Revlimid Rivals Launch Across Europe
Sandoz And Stada Are Among Firms Rolling Out Lenalidomide
Generic versions of Revlimid have been launched in countries across Europe, with Sandoz and Stada among those to have confirmed the introduction of lenalidomide in numerous European markets. Meanwhile, US competition to Revlimid is expected next month.
You may also be interested in...
Stada advances its Specialty ambitions by launching the EU’s first authorized treatment for the rare kidney disease immunoglobulin A nephropathy in the form of its modified-release budesonide capsules.
The company credited generics’ late market entry, but that benefit is not expected to last; the firm lowered guidance for annual sales of the oncologic.
This month, generic competition to several lucrative brands, not least Bristol Myers Squibb’s $8.7bn Revlimid, are set to fall to generic competition in the US. Meanwhile, Sawai is looking to close on a key deal.